Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment
Cancer is associated with single or multiple gene defects. Recently, much research has focused on incorporating genetic materials as one of the means to treat various types of carcinomas. RNA interference (RNAi) conveys an alternative genetic approach for cancer patients, especially when conventiona...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/7/1009 |
id |
doaj-9ac6249e48cc4c8592a41a802a363c7e |
---|---|
record_format |
Article |
spelling |
doaj-9ac6249e48cc4c8592a41a802a363c7e2021-07-23T14:00:36ZengMDPI AGPharmaceutics1999-49232021-07-01131009100910.3390/pharmaceutics13071009Clinical Advances of siRNA-Based Nanotherapeutics for Cancer TreatmentDima Hattab0Amirah Mohd Gazzali1Athirah Bakhtiar2Faculty of Pharmacy, University of Jordan, Queen Rania Street, Amman 11942, JordanSchool of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, MalaysiaSchool of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, MalaysiaCancer is associated with single or multiple gene defects. Recently, much research has focused on incorporating genetic materials as one of the means to treat various types of carcinomas. RNA interference (RNAi) conveys an alternative genetic approach for cancer patients, especially when conventional medications fail. RNAi involves the inhibition of expression of specific messenger RNA that signals for uncontrollable cell growth and proliferation, most notably with carcinoma cells. This molecular technology is promising as genetic materials allow us to overcome issues associated with chemotherapeutic agents including organ damage associated with severe drug toxicities. Nonetheless, vast challenges impede successful gene therapy application, including low tumor localization, low stability and rapid clearance from the blood circulation. Owing to the limited treatment opportunities for the management of cancer, the development of effective siRNA carrier systems involving nanotherapeutics has been extensively explored. Over the past years, several siRNA nanotherapeutics have undergone a period of clinical investigation, with some demonstrating promising antitumor activities and safety profiles. Extensive observation of siRNA-nanoparticles is necessary to ensure commercial success. Therefore, this review mainly focuses on the progress of siRNAs-loaded nanoparticles that have undergone clinical trials for cancer treatment. The status of the siRNA nanotherapeutics is discussed, allowing comprehensive understanding of their gene-mediated therapeutics.https://www.mdpi.com/1999-4923/13/7/1009RNA interferencesmall interfering RNA (siRNA)nanoparticlesclinical trial |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dima Hattab Amirah Mohd Gazzali Athirah Bakhtiar |
spellingShingle |
Dima Hattab Amirah Mohd Gazzali Athirah Bakhtiar Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment Pharmaceutics RNA interference small interfering RNA (siRNA) nanoparticles clinical trial |
author_facet |
Dima Hattab Amirah Mohd Gazzali Athirah Bakhtiar |
author_sort |
Dima Hattab |
title |
Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment |
title_short |
Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment |
title_full |
Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment |
title_fullStr |
Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment |
title_full_unstemmed |
Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment |
title_sort |
clinical advances of sirna-based nanotherapeutics for cancer treatment |
publisher |
MDPI AG |
series |
Pharmaceutics |
issn |
1999-4923 |
publishDate |
2021-07-01 |
description |
Cancer is associated with single or multiple gene defects. Recently, much research has focused on incorporating genetic materials as one of the means to treat various types of carcinomas. RNA interference (RNAi) conveys an alternative genetic approach for cancer patients, especially when conventional medications fail. RNAi involves the inhibition of expression of specific messenger RNA that signals for uncontrollable cell growth and proliferation, most notably with carcinoma cells. This molecular technology is promising as genetic materials allow us to overcome issues associated with chemotherapeutic agents including organ damage associated with severe drug toxicities. Nonetheless, vast challenges impede successful gene therapy application, including low tumor localization, low stability and rapid clearance from the blood circulation. Owing to the limited treatment opportunities for the management of cancer, the development of effective siRNA carrier systems involving nanotherapeutics has been extensively explored. Over the past years, several siRNA nanotherapeutics have undergone a period of clinical investigation, with some demonstrating promising antitumor activities and safety profiles. Extensive observation of siRNA-nanoparticles is necessary to ensure commercial success. Therefore, this review mainly focuses on the progress of siRNAs-loaded nanoparticles that have undergone clinical trials for cancer treatment. The status of the siRNA nanotherapeutics is discussed, allowing comprehensive understanding of their gene-mediated therapeutics. |
topic |
RNA interference small interfering RNA (siRNA) nanoparticles clinical trial |
url |
https://www.mdpi.com/1999-4923/13/7/1009 |
work_keys_str_mv |
AT dimahattab clinicaladvancesofsirnabasednanotherapeuticsforcancertreatment AT amirahmohdgazzali clinicaladvancesofsirnabasednanotherapeuticsforcancertreatment AT athirahbakhtiar clinicaladvancesofsirnabasednanotherapeuticsforcancertreatment |
_version_ |
1721286462208475136 |